Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations
Recruiting
- Conditions
- RPE65-associated inherited retinal degenerations10010463
- Registration Number
- NL-OMON50929
- Lead Sponsor
- Oogziekenhuis Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Scheduled to receive treatment with Luxturna®
Informed consent
Exclusion Criteria
None
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Full-field stimulus testing (FST) at 1 year.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Visual acuity<br /><br>Visual field<br /><br>Mobility course</p><br>